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Antiproliferative Effects of Interferon Alpha on Hepatic
Progenitor Cells In Vitro and In Vivo
Rebecca Lim,1,2 Belinda Knight,1,3 Keyur Patel,4 John G. McHutchison,4 George C. Yeoh,2,3 and John K. Olynyk1,3,5
Hepaticprogenitor cells (calledoval cells in rodents)proliferateduringchronic liver injury.Theyhave
been suggested as targets of malignant transformation in chronic liver diseases, including chronic
hepatitis C. Interferon alpha therapy reduces the risk of hepatocellular carcinoma (HCC) in chronic
hepatitis C regardless of viral clearance. The aim of this study was to determine whether interferon
alpha could reduce the risk ofHCCbymodifying preneoplastic events in the hepatic progenitor cell
population. Pre- and post-treatment liver biopsies were evaluated for changes in the hepatic progen-
itor cell population in 16 patients with non-responding chronic hepatitis C. Interferon alpha–based
treatment signiﬁcantly reduced the numbers of c-kit–positive hepatic progenitor cells by 50%. To
determine themechanismof cell number reduction, the effects of interferon alpha onmurine hepatic
progenitor cells were studied in vitro. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) proliferation assay and proliferating cell nuclear antigen staining showed that interferon
alpha had a dose-dependent, anti-proliferative effect. Interferon alpha stimulated hepatocytic and
biliary differentiation of the oval cell lines reﬂected by increased expression of albumin and cytoker-
atin19 accompaniedbydecreased expressionof alphafetoprotein andThy-1.To validate these results
in vivo,micewereplacedon the choline-deﬁcient, ethionine-supplementeddiet to induce liver injury
andoval cell proliferation and treatedwithpegylated interferonalpha2b for2weeks.This resulted in
a signiﬁcant four-fold reduction in the number of oval cells (P < .05). In conclusion, interferon
alpha–based treatment reduced the number of hepatic progenitor cells in chronic liver injury by
modulating apoptosis, proliferation, and differentiation. Supplementary material for this article can
be found on the HEPATOLOGY website (http://interscience.wiley.com/jpages/0270-9139/suppmat/
index.html). (HEPATOLOGY 2006;43:1074-1083.)
Up to 3% of the world’s populations may be in-fected with hepatitis C virus. Ten percent ofchronically infected individuals progress to cir-
rhosis, with 2% to 9% of subjects with cirrhosis develop-
ing hepatocellular carcinoma (HCC) each year.1-4
Evidence suggests that HCC may arise due to the trans-
formation of adult hepatic progenitor cells, called “inter-
mediate hepatobiliary” cells in humans5 and “oval” cells
in mice.6
In humans, hepatic progenitor cells proliferate after
chronic liver injury due to chronic viral hepatitis, alco-
holic liver disease, or metabolic liver conditions, and their
numbers increase in direct proportion with the disease
severity.7-9 In rodents, oval cells proliferate in response to
a variety of stimuli, primarily associated with exposure to
hepatocarcinogens.10 We have shown in a mouse model
that an attenuated oval cell response correlates with re-
duced incidence of HCC after prolonged liver injury.11
Oval cells are easily transformed in culture, giving rise to
cells capable of forming solid tumors in immune-deﬁcient
mice.12,13 Thus, despite early skepticism, the concept of
progenitor cells as targets of malignant transformation is
now widely accepted, and hence differentiation therapy,
in addition to therapeutic control of proliferation and
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apoptosis of pre-neoplastic cells, is a plausible solution to
overcoming their malignant potential.
Currently, the gold standard for treatment of chronic
hepatitis C infection is combination treatment with inter-
feron alpha and ribavirin.14 In addition to its anti-viral
capabilities, interferon alpha plays an essential role in con-
trolling cellular proliferation and survival of a variety of
diverse cell types, as well as exerting potent immuno-
modulatory and anti-angiogenic actions.15 Interferon al-
pha has been included in the treatment protocols for
malignancies such as hairy-cell leukemia, chronicmyelog-
enous leukemia, and Kaposi’s sarcoma.16 Furthermore,
recent studies have shown that interferon therapy signiﬁ-
cantly reduces the risk for development of HCC, regard-
less of sustained virological response.17-21 This effect
could be mediated via pre-neoplastic effects on the he-
patic progenitor cell compartment. Thus, the aim of this
study was to determine the effect of interferon alpha ther-
apy on the numbers of hepatic progenitor cells observed
in the livers of patients with chronic hepatitis C and to
elucidate the effects of interferon alpha on the behavior of
oval cells in experimental murine models, in vitro and in
vivo.
Methods
Human Studies. Liver biopsies collected before and
after interferon-based treatment were available from 16
randomly selected individuals with non-responding
chronic hepatitis C (predominantly genotype 1). The in-
terval between pre- and post-treatment biopsies was 18
months; patients were treated for 48 weeks and the post-
treatment biopsy was performed at 6 months after end of
treatment. Initial METAVIR scores ranged from 0 to 4.
Informed consent was obtained for the use of these biop-
sies for research purposes, and the study was approved by
the Human Research Ethics Committee, Fremantle Hos-
pital, Fremantle,Western Australia. Standard histological
examination was undertaken using hematoxylin-eosin
and Masson’s trichrome staining for assessment of ﬁbro-
sis.
Human Liver Immunohistochemistry. All sections
were antigen retrieved in citrate buffer (10 mmol/L citric
acid, pH 6.8) by boiling for 15 minutes as described by
Pileri et al.22 Sections were blocked for endogenous per-
oxidases and endogenous biotin using a biotin-blocking
system (Dako, Carpinteria, CA) according to the manu-
facturer’s instructions. Sections were then blocked for
non-speciﬁc antigens using serum-free protein block
(Dako). Primary antibodies against, c-kit (1:200, Dako),
CK19 (1:100, Dako) and -GST (1:400, Rockland, Gil-
bertsville, PA) were applied to tissue sections and incu-
bated overnight at 4°C. Detection was performed using
theUniversal LSAB2Kit (Dako) and liquidDAB (Dako).
Intermediate hepatobiliary cells were identiﬁed as small
cells with ovoid nuclei and scant cytoplasm that were
immunoreactive for cytokeratin 19 (CK19), -glutathi-
one S-transferase (-GST), or c-kit.
In Vitro Oval Cell Studies. Well-characterized im-
mortalized murine oval cell lines (PIL-2 and PIL-4) that
exhibit phenotypic similarities with oval cells in vivo were
used for in vitro studies.12,23,24 PIL cells are immunoreac-
tive for the hepatocyte markers albumin and transferrin
and the oval cell markers alpha-fetoprotein (AFP), A6 and
M2-pyruvate kinease (MPK). They are capable of differ-
entiating along both the hepatic and biliary lineages24 and
exhibit increased proliferation in response to increasing
concentrations of serum.25 PIL-2 cells are tumorigenic
whereas PIL-4 cells are not.12 PIL cells weremaintained in
culture as previously described.12
In Vitro Proliferation Studies. PIL-2 and PIL-4 cells
were seeded in 96-well microtiter plates (BD Falcon,
Franklin Lakes, NJ) at a density of 2,000 cells/well. After
adherence, cells were exposed to media containing pegy-
lated interferon alpha 2b (Schering Plough Pty Ltd, Ken-
ilworth, NJ) at various concentrations (0 to 1000 U/mL)
and cultured for 24 hours. Numbers of metabolically
active cells present at the end of the experiment were
determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT)-based assay, which mea-
sures mitochondrial activity.25 Staining for proliferating
cell nuclear antigen (PCNA) was performed to assess the
proliferative status of the cells, using a previously de-
scribed method.26 In brief, cells were ﬁxed using 4% (v/v)
buffered formalin for 8 minutes and 99% ethanol for 2
minutes. Cells were then washed in phosphate-buffered
saline (PBS) and blocked for endogenous peroxidases
with 3% (v/v) hydrogen peroxide for 1 minute, followed
by a biotin blocking step using a biotin blocking system.
Cells were also blocked with a serum-free protein block
for 10 minutes before incubating with the mouse mono-
clonal anti-PCNA primary antibody diluted in PBS at
1:200, for 1 hour at 37°C. After this, cells were washed in
PBS and incubated with biotinylated anti-mouse second-
ary antibody and streptavidin-labeled horseradish perox-
idase using a Universal LSAB2 Kit for 30 minutes each.
Cells positive for PCNA were visualized using liquid
DAB. PCNA-positive cells were counted in 10 sequential
ﬁelds of view and normalized to the total number of cells
present as determined by phase-contrast microscopy. The
percentage of PCNA-positive cells in each ﬁeld were ex-
pressed as mean SEM.
In Vitro Apoptosis Studies. PIL-2 and PIL-4 cells
were seeded in 4-chambered slides (BD Falcon) at a den-
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sity of 200 cells/chamber. After allowing for adherence,
cells were serum-starved overnight before 3 days’ stimu-
lation with 250 IU/mL pegylated interferon alpha 2b.
Apoptotic cells were detected using terminal deoxynu-
cleotidyl transferase-mediated nick-end labeling
(TUNEL) assay (Promega, Madison, WI) according to
manufacturer’s instructions. Cells undergoing apoptosis
were also identiﬁed using Annexin V-ﬂuorescein isothio-
cyanate (Molecular Probes, Eugene, OR) according to the
manufacturer’s protocol.
In Vitro Differentiation Studies. PIL-2 and PIL-4
cells were seeded in 6-well plates at a medium density of
2,000 cells/well and cultured for 8 days in the presence of
pegylated interferon alpha 2b 250 IU/mL. Cells were
then harvested, and total RNA was isolated using TRIzol
(Invitrogen, Calsbad, CA) and converted to cDNA using
the Thermoscript Reverse Transcription System (Invitro-
gen) according to the instructions of the manufacturer.
Quantitative polymerase chain reaction (PCR) was per-
formed using speciﬁc primers directed against murine al-
bumin, CK19, AFP, glucose-6-phosphatase (G6Pase),
and Thy-1. Each reaction contained 1 reaction buffer
(Fisher Biotech, Perth, Australia), 2.5 mmol/L MgCL2
(Fisher Biotech), 0.25 mmol/L dNTPs (Fisher Biotech),
Platinum Taq (Invitrogen, Australia), and 0.25 SYBR
green (Applied Biosystems, Foster City, CA). Quantita-
tive real-time PCR was performed using the Rotorgene
system (Corbett Research, Australia). PlatinumTaq poly-
merase was activated by preincubation at 95°C for 2 min-
utes, before cycling for 40 cycles of 95°C, 20 seconds;
60°C, 20 seconds; and 72°C, 30 seconds. Fluorescence
was measured at the 72°C extension phase. The level of
gene expressionwas determined in arbitrary units by com-
parison with plasmid DNA standards, speciﬁc for the
gene of interest as previously described.24 The levels of
-actin mRNA was determined in the same samples,
again by comparisons with plasmid DNA standards.
Gene expression of each marker was normalized to -ac-
tin levels to account for variation in RNA loading and the
efﬁciency of reverse transcription. Sequences of primers
and product sizes are listed in Table 1.27,28
Animal Studies. To determine the in vivo effects of
pegylated interferon alpha 2b on the hepatic progenitor
cell population, 4-week old C57Bl/6 male mice weighing
between 14 and 16g were placed on the choline-deﬁcient
ethionine-supplemented (CDE) diet to induce prolifera-
tion of the progenitor cells as previously described.11 An-
imals were administered either 105 units pegylated
interferon alpha 2b (Schering Plough) intraperitoneally
once every 3 days or saline (placebo). Administration of
interferon commenced on the ﬁrst day of CDE feeding
and continued for the duration of the experiment. Mice
were sacriﬁced 2 weeks later. Livers were perfused with
saline, and portions of liver were sampled for histological
studies. All animal experiments were performed in a
pathogen-free animal holding facility in accordance with
guidelines of the National Health and Medical Research
Council of Australia and approved by the University of
Western Australia Animal Ethics Committee.
Histology and Immunohistochemistry. Portions of
perfused liver were either ﬁxed in neutral buffered forma-
lin and embedded in parafﬁn or immersed in cryomatrix
(Tissue-Tek OCT, Sakura Finetek, Japan) and snap-fro-
zen in liquid nitrogen. Five-micron sections were cut and
stained for the presence of speciﬁc antigens using immu-
nohistochemistry.
Sections for MPK and phosho-STAT-3 staining were
antigen retrieved in EDTA buffer (1 mmol/L EDTA, pH
8.0) by boiling for 15 minutes as previously described by
Pileri et al.22 Sections were blocked for endogenous per-
oxidases followed by blocking for non-speciﬁc antigens
using serum-free protein block (DAKO). Primary anti-
bodies against PCNA (1:200; DAKO), MPK (1:500;
Rockland, Gilbertsville, PA), A6 (1:30; a gift from Dr
Valentina Factor, National Cancer Institute, National In-
stitute of Health, Bethesda) and phospho-STAT-3 (1:20,
Cell Signaling Technology, Danvers, MA) were applied
to tissue sections and incubated overnight at 4°C and
Table 1. Primers for Target Gene Sequences Analyzed by Quantitative Polymerase Chain Reaction
Target Gene Primer Sequence Product Size Reference
Albumin 5 CTT AAA CCG ATG GGC GAT CTC ACT 130 bp 27
3 CCC CAC TAG CCT CTG GCA AAA T
-fetoprotein 5 TCG TAT TCC AAC AGG AGG 176 bp 27
3 AGG CTT TTG CTT CAC CAG
G6Pase 5 CGC CTT CTA TGT CCT CTT TCC C 459 bp 27
3 GTT TCA GCC ACA GCA ATG CC
CK19 5 CAT GGT TCT TCT TCA GGT AGG C 177 bp 28
3 GCT GCA GAT GCA TTC AGA ACC
Thy-1 5 AAC CAA AAC CTT CGC CTG GAC 231 bp 27
3 AAG CTC ACA AAA GTA GTC GCC C
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detected using biotinylated secondary antibodies and liq-
uid DAB (DAKO, Carpinteria, CA).
In Situ TUNEL Staining. Apoptotic cells were de-
tected in parafﬁn-embedded tissues using the same
TUNEL assay (Promega) as described previously. Modi-
ﬁcations to allow for detection in tissue sections were
made as recommended by the manufacturer.
Cell Counts. Cell counts were performed on an in-
verted phase microscope using a 400 magniﬁcation.
Counts were performed on 10 adjacent, non-overlapping
peri-portal ﬁelds. Total cell number was also counted in
each ﬁeld, for purposes of data normalization. Liver pro-
genitor cells were identiﬁed as cells approximately 10 m
in diameter with ovoid nucleus and scant cytoplasm.
Hepatocytes were identiﬁed as cells 20 m r more in
diameter with round nucleus and abundant cytoplasm.
Where a speciﬁc marker was not used, care was taken to
exclude other cell types, including inﬂammatory cells, en-
dothelial cells, Kupffer cells, and stellate cells, from oval
cell counts.
Statistical Methods. Each in vitro experiment was
performed three times and in duplicate. Data are reported
as the mean SEM. Comparisons between groups were
performed using unpaired t test or Fisher’s exact test
(GraphPad Prism version 4.03 for Windows, San Diego,
CA). Means were deemed to be different for P  .05.
Non-parametric data are reported as median values and
compared using the Mann-Whitney U test (GraphPad
Prism).
Results
Interferon Alpha–Based Therapy Reduced Num-
bers of c-kit–Positive Intermediate Hepatobiliary
Cells in Subjects With Chronic Hepatitis C. Hepatic
progenitor cells were stained using three markers: c-kit,
CK19, and -GST. Each of these correlate to a different
stage of maturation or lineage. c-kit is a hematopoietic
marker speciﬁc to primitive progenitor cells and is
abruptly switched off as the cell differentiates.29-31-GST
is expressed by fetal hepatocytes and duct-like progenitor
cells,32-34 whereas CK-19 is expressed by mature and im-
mature biliary epithelium.35,36 The number of c-kit–pos-
itive intermediate hepatobiliary cells detected in liver
biopsies was reduced by over 50% in 14 of 16 subjects (13
non-responders) post-treatment with interferon alpha
compared with the paired pre-treatment biopsies (pre-
treatment 3.5%  1.0% versus post-treatment 1.7% 
0.5%, P .05, Fig. 1A) (for individual subject details see
Supplementary Table 1). In contrast, no consistent
change in the numbers of intermediate hepatobiliary cells
that were immunoreactive for CK19 (Fig. 1B) or -GST
(Fig. 1C) was observed between pre-and post-interferon
treatment biopsies. Fibrosis scores remained unchanged
in seven subjects, worsened by at least one level in ﬁve
subjects, and improved in three subjects (all non-respond-
ers). Hepatic inﬂammatory activity remained unchanged
in ﬁve subjects, worsened in six subjects, and improved in
ﬁve subjects (3 responders, 2 non-responders).
Pegylated Interferon Alpha 2b Inhibits Oval Cell
Proliferation and Induces Apoptosis In Vitro. To de-
termine whether interferon treatment modulates prolifer-
ation or apoptosis of hepatic progenitor cells, PIL-2 and
PIL-4 cells were grown in increasing concentrations of
pegylated interferon alpha 2b. The results showed a dose-
dependent reduction in metabolically active cells in the
presence of increasing concentrations of interferon as de-
termined by MTT assay (Fig. 2A). Based on these data,
the median lethal dose was determined to be approxi-
Fig. 1. Changes in the numbers of intermediate hepatobiliary cells in
chronic hepatitis C patients after treatment with interferon alpha. There
was a signiﬁcant decrease by at least 50% in the numbers of c-kit–
positive intermediate hepatobiliary cells in 14 of 16 patients (A, P 
.05). The number of CK-19 (B) and -GST (C)–positive intermediate
hepatic progenitor cells did not change.
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mately 250 IU/mL. The reduction in numbers of meta-
bolically active cells was due to a reduction in
proliferation as demonstrated by PCNA staining (P 
.001, Fig. 2B) and increased apoptosis as demonstrated by
TUNEL assay (P  .001, Fig. 2C).
Pegylated Interferon Alpha 2b Induces Hepatic
Progenitor Cell Differentiation In Vitro. To assess
whether interferon alpha treatment of oval cell lines was
associated with an alteration in maturation state, the rel-
ative expression of key hepatic developmental markers
was determined in vitro after treatment with either vehicle
or interferon. After 8 days’ exposure to pegylated inter-
feron alpha 2b, albumin mRNA levels increased by 19-
fold in PIL-2 cells (P .001, Fig. 3A), whereas in PIL-4
cells the levels remained unchanged. CK19 mRNA levels
increased threefold after treatment in both cell lines (P
.05, Fig. 3B, G). PIL-2 and PIL-4 cells exhibited a de-
crease in AFP gene expression of 1- and 323-fold, respec-
tively (Fig. 3C, H). Thy-1 was only expressed in PIL-2
cells, and its expression was signiﬁcantly reduced after
administration of interferon (P  .05, Fig. 3E). G6Pase
mRNA levels increased by 414-fold in PIL-4 cells after
administration of interferon (P  .05, Fig. 3I) but re-
mained unaffected in PIL-2 cells.
Pegylated Interferon Alpha 2b Inhibits Prolifera-
tion of Murine Hepatic Progenitor Cells In Vivo. To
substantiate the in vitro anti-proliferative effects of inter-
feron alpha onmurine oval cells, we induced chronic liver
injury inmice using aCDEdiet, and concurrently admin-
istered either a placebo control or interferon. After 2
weeks of CDE diet feeding, treatment with pegylated in-
terferon alpha 2b resulted in a fourfold reduction in the
number of A6-positive oval cells present in the liver, in
comparison with animals that received placebo (P .05,
Fig. 4). This was accompanied by a one-third decrease of
MPK-positive oval cells (P  .05, Fig. 4).
Fig. 2. Effect of pegylated interferon alpha 2b on proliferation of PIL cells. PIL-2 and PIL-4 cells were cultured with interferon at concentrations
of 500, 250, 125, 62.5, 16.6, 7.8, and 1.95 IU/mL. As the results for both cells types were similar, only the results for PIL-4 cells are presented.
The numbers of PIL-4 cells decreased with increasing concentrations of interferon (A). After 3 days culture with interferon, a 16% decrease in the
numbers of PCNA-positive PIL-4 cells was seen (B) together with a ninefold increase in the numbers of apoptotic cells as detected using TUNEL assay
(C). Annexin V ﬂuorescein isothiocyanate clearly shows increased expression in cells treated with interferon (C). ***P  .001. PCNA, proliferating
cell nuclear antigen; TUNEL, terminal deoxynucleotidyl transferase-mediated nick-end labeling.
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PCNA staining of liver tissues showed that treatment
with interferon alpha 2b resulted in a signiﬁcant reduc-
tion in the numbers of PCNA-positive oval cells, whereas
increasing numbers of PCNA-positive hepatocytes (P 
.05, Fig. 5A). No signiﬁcant effect on apoptosis of either
cell type was evident fromTUNEL staining of interferon-
or placebo-treated livers (P  .001, Fig. 5B).
Pegylated Interferon Alpha 2b Treatment Induces
Stat-3 Phosphorylation in Hepatic Cells. STAT-3 is
known to be a major downstream mediator in the inter-
feron alpha signaling pathway and has been implicated in
the control of oval cell proliferation and differentiation in
vitro.24,25,37 To determine whether STAT-3 phosphoryla-
tionmay be involved in themediation of interferon effects
in the CDE model, numbers of phosphorylated STAT-
3–positive cells were assessed in the livers of interferon- or
placebo-treated animals. Pegylated interferon alpha 2b–
treated mice had signiﬁcantly increased numbers of phos-
Fig. 3. Change in expression of differentiation markers after treatment with pegylated interferon alpha 2b. After 8 days treatment with 250 IU/mL
interferon, quantitative PCR was performed to analyze changes in gene expression. Signiﬁcant increases in expression of albumin (A) and CK-19 (B)
were observed in PIL-2 cells accompanied by a marked decrease in the expression of AFP (D) and Thy-1 (E). PIL-4 cells demonstrated increased
CK-19 (B) and G6Pase (C) expression and substantially reduced expression of AFP (D) after co-culture with interferon. *P .05, **P .01, ***P
.001. PCR, polymerase chain reaction; AFP, alpha-fetoprotein.
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phorylated STAT-3–positive cells compared with
placebo, conﬁrming the activation of this signaling path-
way after interferon treatment (P  .001, Fig. 6).
Discussion
Interferon alpha has been suggested to exert anti-tu-
morigenic effects in the livers of patients with chronic
hepatitis C independent of its anti-viral capabilities.
Mounting evidence suggests that at least a subset of liver
tumors occurring in mice and humans might arise due to
transformation of adult liver progenitor cells. As such, we
investigated the effects of interferon treatment in human
subjects with chronic hepatitis C and in the injury-in-
duced murine liver progenitor cell compartment, to de-
termine whether it modulates the behavior of these cells,
in vitro and in vivo.
Treatment with interferon alpha reduced the num-
bers of c-kit–positive intermediate hepatobiliary cells
in 14 of 16 non-responding subjects with chronic hep-
atitis C. C-kit is a well-described marker for hepatic
progenitor cells,26,34,38 and has been previously studied
in human liver biopsies from patients with viral hepa-
titis, both with and without HCC.34,39,40 Furthermore,
we have recently shown that numbers of c-kit–positive
cells in patients with chronic hepatitis B correlate with
disease severity (Knight B et al, unpublished observa-
tions). Selective targeting of the c-kit cell population
has also been suggested to offer potential beneﬁts in the
treatment of HCC.41 Previous reports have suggested
that a subset of c-kit– expressing hepatic progenitor
cells also express CK19.38,42 Numbers of CK19–posi-
tive cells were not affected in our study; this suggests
that the anti-tumorigenic effects of interferon therapy
in patients with hepatitis C may be mediated by selec-
tive reduction of the c-kit–positive, CK19- negative
progenitor cell pool. The signiﬁcance of this subset of
hepatic progenitor cells in the pathogenesis of chronic
viral hepatitis is not yet known, and warrants further
exploration.
To elucidate the mechanism by which interferon
alpha treatment reduced the numbers of intermediate
hepatobiliary cells present in the chronic hepatitis C
patients, we examined the effects of pegylated inter-
feron alpha 2b on the proliferation, apoptosis, and dif-
ferentiation of two well-characterized murine oval cell
lines. The results suggest that interferon may exert di-
rect effects on hepatic progenitor cells, reducing their
rate of cell growth as well as stimulating them to un-
dergo apoptosis. This is in accordance with the ob-
served effects of interferon on human HCC-derived
0.0
0.5
1.0
1.5
2.0
2.5
*
%
 P
C
N
A
-p
o
si
ti
ve
 o
va
l c
el
ls
Placebo IFN a
0
1
2
3
***
%
 P
C
N
A
-p
o
si
ti
ve
 h
ep
at
o
cy
te
s
Placebo IFN a
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
%
 T
U
N
E
L
-p
o
si
ti
ve
 o
va
l c
el
ls
0.00
0.25
0.50
0.75
1.00
1.25
%
 T
U
N
E
L
-p
o
si
ti
ve
 h
ep
at
o
cy
te
s
Placebo IFN a
Placebo IFN a
A B
Fig. 5. Pegylated interferon alpha 2b exerts differential effects on
proliferation of oval cells versus hepatocytes but does not appear to
affect apoptosis in either cell type in vivo. Administration of pegylated
interferon alpha 2b reduced the proportion of PCNA-positive oval cells
but increased the proportion of PCNA-positive hepatocytes compared
with placebo (A). Pegylated interferon alpha 2b did not increase apo-
ptosis in hepatocytes or oval cells, as judged by TUNEL staining (B).
*P .05, ***P .001. PCNA, proliferating cell nuclear antigen; TUNEL,
terminal deoxynucleotidyl transferase-mediated nick-end labeling.
Fig. 4. Pegylated interferon alpha 2b causes a reduction in numbers
of hepatic progenitor cells in mice fed the CDE diet. Administration of
pegylated interferon alpha 2b to mice fed the CDE diet for 2 weeks
resulted in substantial reductions in the percentages of A6- and MPK-
positive hepatic progenitor (oval) cells compared with mice treated with
placebo. *P  .05. CDE diet, Choline deﬁcient ethionine supplemented
diet.
1080 LIM ET AL. HEPATOLOGY, May 2006
cell lines, in which interferon alpha caused delayed
S-phase progression through inhibition of cyclin-de-
pendent kinases42 and induced caspase-dependent ap-
optosis.43 Interestingly, after treating PIL-2 and PIL-4
cells with interferon alpha for 8 days, signiﬁcant
changes were observed in the expression of various
marker genes corresponding to different stages of he-
patic progenitor cell maturity and lineage. The expres-
sion of the immature cell markers AFP and Thy-1 was
dramatically reduced after culture in the presence of
interferon alpha, suggesting that their maturation was
cytokine stimulated. These ﬁndings were corroborated
by the increased expression of the mature biliary and
hepatocytic markers CK19, albumin, and G6Pase in
one or both of the cell lines. This suggests that in
addition to its growth-modulatory effects, interferon
alpha may promote the maturation of liver progenitor
cells.
Previous studies in rodents have shown that inter-
feron treatment inhibits hepatocarcinogenesis via anti-
proliferative effects; however, these studies did not
address whether this was associated with a reduction in
the oval cell response.18 In the current work we showed
that interferon therapy in the CDE model of hepato-
carcinogenesis reduced the number of A6- and MPK-
positive oval cells compared with placebo. Our ﬁndings
also suggest that interferon alpha 2b exerts a differen-
tial effect on the proliferation of oval cells compared
with hepatocytes, increasing numbers of PCNA-posi-
tive hepatocytes but reducing numbers of PCNA-pos-
itive oval cells. This implies some degree of speciﬁcity
involved in the interferon alpha 2b–induced inhibition
of proliferation. However, the number of TUNEL-
positive oval cells or hepatocytes did not change signif-
icantly in interferon alpha–treated livers, suggesting
that the reduced numbers of progenitor cells seen in
vivo was likely to be mediated primarily through re-
duced growth or increased maturation, rather than by a
direct apoptotic mechanism.
The observed discrepancy between the apoptosis-in-
ducing effects of interferon alpha on oval cells in vitro and
in vivo could be due to one or more of several reasons: (1)
a dose dependence, whereby in vivo oval cells were not
exposed to high enough concentrations of interferon to
induce signiﬁcant apoptosis, or (2) a time dependence,
whereby most of the apoptotic effects on the oval cell
population induced by interferon occurred before or after
the 2-week time point, when samples were examined.
Alternately, the discrepancy may simply reﬂect the limi-
tation of cell culture systems for predicting in vivo biolog-
ical effects; cell– cell interactions, as well as circulating
co-factors, may signiﬁcantly modify the effect of direct
cytokine stimulation on isolated cells.
In this study we show that interferon alpha treat-
ment increases the numbers of cells expressing phos-
phorylated STAT-3, a key component and multi-
faceted member of the Jak-STAT signaling pathway.
STAT-3 activation has been shown in previous studies
to be associated with differentiation of hepatic progen-
itor cells.44,45 Furthermore, we have shown that phos-
phorylated STAT-3 inhibits proliferation and
promotes apoptosis of the PIL cell lines.24 Thus, we
propose that the molecular events leading to the inhi-
bition of proliferation and differentiation of hepatic
progenitor cells in response to interferon treatment
may be mediated by STAT-3. Future studies using
siRNA technology to knockdown STAT-3 expression
in our cell lines are planned to test this hypothesis.
In conclusion, interferon-based therapy of human
subjects with chronic hepatitis C, or rodents with ex-
perimentally induced liver injury, results in a reduction
in the numbers of hepatic progenitor cells. Our results
suggest that these effects may be mediated by direct
effects of interferon on the hepatic progenitor cell com-
partment, including inhibition of proliferation, induc-
tion of apoptosis, and promotion of differentiation.
These ﬁndings provide further support for the concept
that interferon-based therapies reduce the risk of HCC
by modulating the response of intermediate hepatobili-
Fig. 6. Pegylated interferon alpha 2b increases the numbers of phos-
phorylated STAT-3–positive cells in the liver. A signiﬁcant increase in the
percentage of cells positive for phosphorylated STAT-3 was observed in
the livers of mice treated with pegylated interferon alpha 2b, compared
with placebo. ***P  .001.
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ary cells in chronic hepatitis C. Our results support the
suggestion made previously that even non-responders
may beneﬁt from continued interferon therapy20,46,47
and strongly suggest that the anti-carcinogenic proper-
ties of interferon alpha in the liver should be explored
further.
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